Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues

Cancer Research

Volumn 59, Issue 7, 1999, Pages 1626-1634

  Tozer, Gillian M ^a   Prise, Vivien E ^a   Wilson, John ^a   Locke, Rosalind J ^a   Vojnovic, Borivoj ^a   Stratford, Michael R L ^a   Dennis, Madeleine F ^a   Chaplin, David J ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOSARCOMA; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG EFFICACY; DRUG TARGETING; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR VASCULARIZATION;

EID: 0033119771     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Chaplin, D. J., and Dougherty, G. J. Tumor vasculature as a target for cancer therapy. Br. J. Cancer, in press, 1999.
2. Lewis, C. E., Bicknell, R., and Ferrara, N. Tumor Angiogenesis. Oxford: Oxford Univ. Press, 1997.
3. Marshall, J. L., and Hawkins, M. J. The clinical experience with antiangiogenic agents. Breast Cancer Res. Treat., 36: 253-261, 1995.
4. Denis, L. J., and Verweij, J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest. New Drugs, 15: 175-185, 1997.
5. Twardowski, P., and Gradishar, W. J. Clinical trials of antiangiogenic agents. Curr. Opin. Oncol., 9: 584-589, 1997.
6. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
7. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
8. Burrows, F. J., and Thorpe, P. E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA, 90: 8996-9000, 1993.
9. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., and Thorpe, P. E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science (Washington DC), 24: 547-550, 1997.
10. Hill, S. A., Lonergan, S. J., Denekamp, J., and Chaplin, D. J. Vinca alkaloids: anti-vascular effects in a murine tumor. Eur. J. Cancer, 29A: 1320-1324, 1993.
11. Chaplin, D. J., Pettit, G. R., Parkins, C. S., and Hill, S. A. Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents. Br. J. Cancer, 74 (Suppl. 27): S86-S88, 1996.
12. Bibby, M. C., Double, J. A., Loadman, P. M., and Duke, C. V. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J. Natl. Cancer Inst., 81: 216-220, 1989.
13. Zwi, L. J., Baguley, B. C., Gavin, J. B., and Wilson, W. R. Blood now failure as a major determinant in the antitumor action of flavone acetic acid. J. Natl. Cancer Inst., 81: 1005-1013, 1989.
14. Hill, S. A., Sampson, L. E., and Chaplin, D. J. Anti-vascular approaches to solid tumor therapy: evaluation of vinblastine and flavone acetic acid. Int. J. Cancer, 63: 119-123, 1995.
15. Seed, L., Slaughter, D. P., and Limarzi, L. R. Effect of colchicine on human carcinoma. Surgery (St. Louis), 7: 696-709, 1940.
16. Pettit, G. R., Singh, S. B., Hamel, E., Lin, C. M., Alberts, D. S., and Garia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A4. Experientia, 45: 205-211, 1989.
17. Woods, J. A., Hadfield, J. A., Pettit, G. R., Fox, B. W., and McGown, A. T. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br. J. Cancer, 71: 705-711, 1995.
18. Dorr, R. T., Dvorakova, K., Snead, K., Alberts, D. S., Salmon, S. E., and Pettit, G. R. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest. New Drugs, 14: 131-137, 1996.
19. Pettit, G. R., Temple, C., Narayanan, V. L., Varma, R., Simpson, M. J., Boyd, M. R., Rener, G. A., and Bansal, N. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Design, 10: 299-309, 1995.
20. Dark, G. D., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., and Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res., 57: 1829-1834, 1997.
21. Chaplin, D. J., Pettit, G. R., and Hill, S. A. Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res., in press, 1999.
22. Parkins, C. S., Dennis, M. F., Stratford, M. R. L., Hill, S. A., and Chaplin, D. J. Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide. Cancer Res., 55, 6026-6029, 1995.
23. Parkins, C. S., Hill, S. A., Stratford, M. R. L., Dennis, M. F., and Chaplin, D. J. Metabolic and clonogenic consequences of ischaemia-reperfusion insult in solid tumors. Exp. Physiol., 82: 361-368, 1997.
24. Thomsen, L. I., Ching. L-M., Zhuang, L., Gavin, J B., and Baguley, B. C. Tumor-dependent increased plasma nitrate concentrations as an indication of the anti-tumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res., 51: 77-81, 1991.
25. Harris, S. R., and Thorgeirsson, U. P. Flavone acetic acid stimulates nitric oxide and peroxynitrite production in subcutaneous mouse tumors. Biochem. Biophys. Res. Commun., 235; 509-514, 1997.
26. Stuehr, D. J., and Nathan, C. F. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med., 169: 1543-1555, 1989.
27. Farias-Eisner, R., Sherman, M. P., Aeberhard, E., and Chaudhuri, G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc. Natl. Acad. Sci. USA, 91: 9407-9411, 1994.
28. Wink, D. A., Hanbauer, I., Krishna, M. C., DeGraff, W., Gamson, J., and Mitchell, J. B. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc. Natl. Acad. Sci. USA, 90: 9813-9817, 1993.
29. Tozer, G. M., and Shaffi, K. M. Modification of tumor blood flow using the hypertensive agent, angiotensin II. Br. J. Cancer, 67: 981-988, 1993.
30. Kety, S. S. Theory of blood tissue exchange and its application to measurements of blood flow. Methods Med. Res, 8: 223-227, 1960.
31. Tozer, G. M., Shaffi, K. M., Prise, V. E., and Cunningham, V. J. Characterisation of tumor blood flow using a "tissue-isolated" preparation. Br. J. Cancer, 70: 1040-1046, 1994.
32. Stratford, M. R. L., and Dennis, M. F. Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography. J. Chromatogr. B., 721: 77-85, 1999.
33. Tozer, G. M., Prise, V. E., and Chaplin, D. J. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res., 57: 948-955, 1997.
34. Dvorak, H. F., Nagy, J. A., Dvorak, J. T., and Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133: 95-109, 1988.
35. Boucher, Y., Baxter, L. T., and Jain, R. K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res., 50: 4478-4484, 1990.
36. Tozer, G. M., and Everett, S. A. Nitric oxide in tumor biology and cancer therapy. Part 1: physiological aspects. Clin. Oncol., 9: 282-293, 1997.
37. Thiemermann, C. Nitric oxide and septic shock. Gen. Pharmacol., 29: 159-166, 1997.
38. Tozer, G. M., Prise, V. E., Bell, K. M., Dennis, M. F., Stratford, M. R. L., and Chaplin, D. J. Reduced capacity of tumor blood vessels to produce EDRF: significance for tumor blood flow modification Br. J. Cancer. 74: 1955-1960, 1996.
39. Kennovin, G. D., Flitney, F. W., and Hirst, D. G. "Upstream" modification of vasoconstrictor responses in rat epigastric artery supplying an implanted tumor. In: P. Vaupel (ed.), Oxygen Transport to Tissue XV, pp. 411-416. New York: Plenum Press, 1994.
40. Griffith, T. M. Temporal chaos in the microcirculation. Cardiovasc. Res., 31: 342-358, 1996.
41. Gomori, G. Microtechnical demonstration of phosphatase in tissue sections. Proc. Soc. Exp. Biol. Med., 42: 23-28, 1939.
42. Murray, J. C., Smith, K. A., and Lauk, S. Vascular markers for murine tumors. Radiother. Oncol., 16: 231-234, 1989.
43. Peters, G. J., and van der Vijgh, W. J. F. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Eur. J. Cancer, 31A (Suppl. 1): S1-S7, 1995.